Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Biochemically Recurrent Prostate Cancer Clear all
Completed Phase 2 Interventional Results available

Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer

NCT00499408
View directory record Official record
Conditions
Prostate Cancer
Interventions
Vitamin D, soy
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

NCT00925600
View directory record Official record
Conditions
Cancer, Cataract, Low Bone Mineral Density, Osteopenia, Osteoporosis, Prostate Cancer
Interventions
Denosumab, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
30 Years to 120 Years · Male only
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
52
States / cities
Anaheim, California • Laguna Hills, California • Murrieta, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 10, 2026, 8:10 AM EDT
Withdrawn No phase listed Observational

Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly

NCT00161252
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
75 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 2 Interventional

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

NCT02020070
View directory record Official record
Conditions
Metastatic Castration Sensitive Prostate Cancer
Interventions
Degarelix, Ipilimumab, Radical Prostatectomy
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer

NCT01054079
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
laboratory biomarker analysis, quality-of-life assessment, questionnaire administration, cinacalcet hydrochloride
Other · Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 10, 2026, 8:10 AM EDT
Terminated Phase 2 Interventional Results available

Perifosine in Treating Patients With Recurrent Prostate Cancer

NCT00058214
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
perifosine, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Sep 10, 2026, 8:10 AM EDT
Terminated Phase 2 Interventional Results available

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

NCT04336943
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Durvalumab, Olaparib, Quality-of-Life Assessment, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 1 Interventional

68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

NCT04216134
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma
Interventions
Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography
Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

NCT00838201
View directory record Official record
Conditions
Cancer, Carcinoma, Castrate-Resistant Prostate Cancer, Prostate Cancer, Tumors
Interventions
Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
27
States / cities
Huntsville, Alabama • Anaheim, California • Laguna Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

Prostvac in Patients With Biochemically Recurrent Prostate Cancer

NCT02649439
View directory record Official record
Conditions
Prostate Cancer
Interventions
PROSTVAC -V, PROSTVAC-F
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 10, 2026, 8:10 AM EDT
Withdrawn Phase 2 Interventional

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

NCT04585932
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Apalutamide, Degarelix, Leuprolide Acetate, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer

NCT00379561
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA-Activated PSA-PAH1
Drug
Lead sponsor
Sophiris Bio Corp
Industry
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 10, 2026, 8:10 AM EDT
Recruiting Phase 2 Interventional

Radiation Therapy Approaches for People With Prostate Cancer

NCT07751159
View directory record Official record
Conditions
Prostate Cancer Patients, Non-metastatic Prostate Cancer, High Risk Prostate Cancer
Interventions
Standard of Care HDR Brachytherapy, SBRT
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Not applicable Interventional

A Study of Grape Seed Extract in Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising PSA

NCT03087903
View directory record Official record
Conditions
Prostate Cancer
Interventions
Grape Seed Extract
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 10, 2026, 8:10 AM EDT
Suspended Phase 2 Interventional

White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA

NCT04519879
View directory record Official record
Conditions
Prostate Adenocarcinoma, PSA Failure, PSA Progression, Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Clinical Observation, Patient Observation, Questionnaire Administration, White Button Mushroom Extract
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Duarte, California • Glendora, California • Irvine, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 10, 2026, 8:10 AM EDT
Terminated Phase 2 Interventional

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

NCT04928820
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 10, 2026, 8:10 AM EDT
Terminated Phase 2 Interventional Results available

18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer

NCT04727736
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL
Drug
Lead sponsor
Ashok Muthukrishnan
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

NCT04523207
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, ADT, Relugolix
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
32
States / cities
Tucson, Arizona • Little Rock, Arkansas • Sherman Oaks, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer

NCT01341652
View directory record Official record
Conditions
Prostate Cancer
Interventions
pTVG-HP, rhGM-CSF
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 10, 2026, 8:10 AM EDT
Terminated Phase 2 Interventional Results available

Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer

NCT00670046
View directory record Official record
Conditions
Prostate Cancer
Interventions
valproic acid, standard of care follow-up
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 1 Interventional

White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy

NCT00779168
View directory record Official record
Conditions
Prostate Cancer
Interventions
white button mushroom extract, flow cytometry, immunologic technique, laboratory biomarker analysis, gas chromatography-mass spectrometry, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 10, 2026, 8:10 AM EDT
Completed No phase listed Observational

An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States

NCT06204302
View directory record Official record
Conditions
Non-metastatic Prostate Cancer, Non-metastatic Castration-resistant Prostate Cancer
Interventions
Darolutamide (Nubeqa, BAY1841788), Enzalutamide, Apalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 10, 2026, 8:10 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

NCT03047135
View directory record Official record
Conditions
Prostate
Interventions
Olaparib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Omaha, Nebraska • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide

NCT05526248
View directory record Official record
Conditions
Biochemically Recurrent Prostate Cancer
Interventions
Darolutamide(BAY1841788, Nubeqa), Enzalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Sherman Oaks, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 10, 2026, 8:10 AM EDT